{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:39:25Z","timestamp":1753889965059,"version":"3.41.2"},"reference-count":42,"publisher":"Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,29]]},"DOI":"10.31744\/einstein_journal\/2022ao6859","type":"journal-article","created":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T13:08:59Z","timestamp":1651583339000},"source":"Crossref","is-referenced-by-count":0,"title":["Quality of clinical studies present in the package inserts of coagulation factors used in the treatment of hemophilia"],"prefix":"10.31744","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5218-3190","authenticated-orcid":false,"given":"Yasmin Gon\u00e7alves","family":"Ara\u00fajo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7981-6763","authenticated-orcid":false,"given":"Jo\u00e3o Pedro Vasconcelos","family":"Paolinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5219-5706","authenticated-orcid":false,"given":"Janaina Souza Dias","family":"Pichitelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6377-241X","authenticated-orcid":false,"given":"Danyelle Romana Alves","family":"Rios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3400-0725","authenticated-orcid":false,"given":"Nayara Ragi","family":"Baldoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6379-0415","authenticated-orcid":false,"given":"Andr\u00e9 Oliveira","family":"Baldoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16942","reference":[{"issue":"3","key":"key20220503090854_B1","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1046\/j.1365-2516.2002.00633.x","article-title":"Rare coagulation deficiencies","volume":"8","author":"Peyvandi","year":"2002","unstructured":"1. Peyvandi F, Duga S, Akhavan S, Mannucci PM. Rare coagulation deficiencies. Haemophilia. 2002;8(3):308-21. Review.","journal-title":"Haemophilia"},{"key":"key20220503090854_B2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2147\/JBM.S68234","article-title":"Hemophilia A in Brazil- epidemiology and treatment developments","volume":"5","author":"Ferreira","year":"2014","unstructured":"2. Ferreira AA, Leite IC, Bustamante-Teixeira MT, Guerra MR. Hemophilia A in Brazil- epidemiology and treatment developments. J Blood Med. 2014;5:175-84. Review.","journal-title":"J Blood Med"},{"key":"key20220503090854_B3","author":"Brasil","year":"2018","unstructured":"3. Brasil. Minist\u00e9rio da Sa\u00fade. Secretaria de Aten\u00e7\u00e3o \u00e0 Sa\u00fade. Departamento de Aten\u00e7\u00e3o Especializada e Tem\u00e1tica. Perfil das coagulopatias heredit\u00e1rias: 2016. Bras\u00edlia (DF): Minist\u00e9rio da Sa\u00fade; 2018 [citado 2021 Fev 18]. Dispon\u00edvel em: https:\/\/bvsms.saude.gov.br\/bvs\/publicacoes\/perfil_coagulopatias_ hereditarias_2016.pdf","journal-title":"Perfil das coagulopatias heredit\u00e1rias: 2016"},{"issue":"10040","key":"key20220503090854_B4","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0140-6736(15)01123-X","article-title":"The past and future of haemophilia: diagnosis, treatments, and its complications","volume":"388","author":"Peyvandi","year":"2016","unstructured":"4. Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet. 2016;388(10040):187-97. Review.","journal-title":"Lancet"},{"key":"key20220503090854_B5","author":"Brasil","year":"2015","unstructured":"5. Brasil. Minist\u00e9rio da Sa\u00fade. Secretaria de Aten\u00e7\u00e3o \u00e0 Sa\u00fade. Departamento de Aten\u00e7\u00e3o Especializada e Tem\u00e1tica. Manual de hemofilia. Bras\u00edlia (DF): Minist\u00e9rio da Sa\u00fade; 2015 [citado 2021 Fev 18]. Dispon\u00edvel em: https:\/\/bvsms.saude.gov.br\/bvs\/publicacoes\/manual_hemofilia_2ed.pdf","journal-title":"Manual de hemofilia"},{"key":"key20220503090854_B6","author":"Brasil","year":"2009","unstructured":"6. Brasil. Minist\u00e9rio da Sa\u00fade. Secretaria de Aten\u00e7\u00e3o \u00e0 Sa\u00fade. Departamento de Aten\u00e7\u00e3o Especializada. Hemofilia cong\u00eanita e inibidor: manual de diagn\u00f3stico e tratamento de eventos hemorr\u00e1gicos. Bras\u00edlia (DF): Minist\u00e9rio da Sa\u00fade; 2009 [S\u00e9rie A. Normas e Manuais T\u00e9cnicos] [citado 2021 Fev 18]. Dispon\u00edvel em: https:\/\/bvsms.saude.gov.br\/bvs\/publicacoes\/hemofilia_congenita_inibidor_diagnostico_tratamento.pdf","journal-title":"Hemofilia cong\u00eanita e inibidor: manual de diagn\u00f3stico e tratamento de eventos hemorr\u00e1gicos"},{"key":"key20220503090854_B7","author":"Brasil","year":"2019","unstructured":"7. Brasil. Minist\u00e9rio da Sa\u00fade. Governo do Brasil. Minist\u00e9rio da Sa\u00fade garante R$ 1,3 bilh\u00e3o para tratamento de hemof\u00edlicos. Bras\u00edlia (DF): Minist\u00e9rio da Sa\u00fade; 2019 [citado 2021 Mar 25]. Dispon\u00edvel em: https:\/\/www.gov.br\/pt-br\/noticias\/saude-e-vigilancia-sanitaria\/2019\/04\/ministerio-da-saude-garanter-1-3-bilhao-para-tratamento-de-hemofilicos","journal-title":"Minist\u00e9rio da Sa\u00fade garante R$ 1,3 bilh\u00e3o para tratamento de hemof\u00edlicos"},{"issue":"6","key":"key20220503090854_B8","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1111\/bcp.13206","article-title":"Evaluating beneficial drug effects in a non-interventional setting: a review of effectiveness studies based on Swedish Prescribed Drug Register data","volume":"83","author":"Wallerstedt","year":"2017","unstructured":"8. Wallerstedt SM, Hoffmann M. Evaluating beneficial drug effects in a non-interventional setting: a review of effectiveness studies based on Swedish Prescribed Drug Register data. Br J Clin Pharmacol. 2017;83(6):1309-18. Review.","journal-title":"Br J Clin Pharmacol"},{"key":"key20220503090854_B9","author":"Brasil","year":"1976","unstructured":"9. Brasil. C\u00e2mara dos Deputados. Centro de Documenta\u00e7\u00e3o e Informa\u00e7\u00e3o. Lei n. 6.360, de 23 de Setembro de 1976. Disp\u00f5e sobre a vigil\u00e2ncia sanit\u00e1ria a que ficam sujeitos os medicamentos, as drogas, os insumos farmac\u00eauticos e correlatos, cosm\u00e9ticos, saneantes e outros produtos, e d\u00e1 provid\u00eancias. Bras\u00edlia (DF): Di\u00e1rio Oficial da Uni\u00e3o; 1976 [citado 2021 Mar 25]. Dispon\u00edvel em: https:\/\/www2.camara.leg.br\/legin\/fed\/lei\/1970-1979\/lei-6360-23-setembro-1976-357079-normaatualizada-pl.html","journal-title":"Lei n. 6.360, de 23 de Setembro de 1976. Disp\u00f5e sobre a vigil\u00e2ncia sanit\u00e1ria a que ficam sujeitos os medicamentos, as drogas, os insumos farmac\u00eauticos e correlatos, cosm\u00e9ticos, saneantes e outros produtos, e d\u00e1 provid\u00eancias"},{"issue":"4","key":"key20220503090854_B10","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1590\/S0102-311X2008000400003","article-title":"Evolu\u00e7\u00e3o hist\u00f3rica das bulas de medicamentos no Brasil","volume":"24","author":"Caldeira","year":"2008","unstructured":"10. Caldeira TR, Neves ER, Perini E. Evolu\u00e7\u00e3o hist\u00f3rica das bulas de medicamentos no Brasil. Cad Saude Publica. 2008;24(4):737-43. Review.","journal-title":"Cad Saude Publica"},{"key":"key20220503090854_B11","author":"Brasil","year":"2010","unstructured":"11. Brasil. Resolu\u00e7\u00e3o RDC n\u00ba 47, de 8 de setembro de 2009. Estabelece regras para elabora\u00e7\u00e3o, harmoniza\u00e7\u00e3o, atualiza\u00e7\u00e3o, publica\u00e7\u00e3o e disponibiliza\u00e7\u00e3o de bulas de medicamentos para pacientes e para profissionais de sa\u00fade. Bras\u00edlia (DF): Di\u00e1rio Oficial da Uni\u00e3o, 19 jan, 2010 [citado 2021 Mar 26]. Dispon\u00edvel em: https:\/\/pesquisa.in.gov.br\/imprensa\/jsp\/visualiza\/index.jsp?data=19\/01\/2010&jornal=1&pagina=36&totalArquivos=72","journal-title":"Resolu\u00e7\u00e3o RDC n\u00ba 47, de 8 de setembro de 2009. Estabelece regras para elabora\u00e7\u00e3o, harmoniza\u00e7\u00e3o, atualiza\u00e7\u00e3o, publica\u00e7\u00e3o e disponibiliza\u00e7\u00e3o de bulas de medicamentos para pacientes e para profissionais de sa\u00fade"},{"issue":"2","key":"key20220503090854_B12","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1590\/S0034-89102000000200013","article-title":"Bulas de medicamentos e a informa\u00e7\u00e3o adequada ao paciente","volume":"34","author":"da Silva","year":"2000","unstructured":"12. da Silva T, Dal-Pizzol F, Bello CM, Mengue SS, Schenkel EP. Bulas de medicamentos e a informa\u00e7\u00e3o adequada ao paciente. Rev Saude Publica. 2000;34(2):184-9.","journal-title":"Rev Saude Publica"},{"key":"key20220503090854_B13","first-page":"251","volume-title":"Epidemiologia","author":"Escosteguy","year":"2008","unstructured":"13. Escosteguy, CC. Estudos de Interven\u00e7\u00e3o. In: Medronho RA. Epidemiologia. 2a ed. S\u00e3o Paulo: Atheneu; 2008. p. 251-63.","edition":"2a"},{"key":"key20220503090854_B14","article-title":"Nya l\u00e4kemedel kan nomineras f\u00f6r introduktionsfinansiering - Prioriteringen bygger p\u00e5 medicinsk och vetenskaplig v\u00e4rdering \u2013 goda erfarenheter fr\u00e5n process i V\u00e4stra G\u00f6talandsregionen","volume":"113","author":"Wallerstedt","year":"2016","unstructured":"14. Wallerstedt S. Nya l\u00e4kemedel kan nomineras f\u00f6r introduktionsfinansiering - Prioriteringen bygger p\u00e5 medicinsk och vetenskaplig v\u00e4rdering \u2013 goda erfarenheter fr\u00e5n process i V\u00e4stra G\u00f6talandsregionen. Lakartidningen. 2016; 113:D43D.","journal-title":"Lakartidningen"},{"key":"key20220503090854_B15","first-page":"57","article-title":"Ensaios Cl\u00ednicos em Medicamentos","author":"Borges","year":"2013","unstructured":"15. Borges M. Ensaios Cl\u00ednicos em Medicamentos. Revista Portuguesa de Cirurgia. 2013:57-63.","journal-title":"Revista Portuguesa de Cirurgia"},{"issue":"7","key":"key20220503090854_B16","first-page":"632","article-title":"Hemophilia burden of disease: a systematic review of the cost-utility literature for hemophilia","volume":"24","author":"Thorat","year":"2018","unstructured":"16. Thorat T, Neumann PJ, Chambers JD. Hemophilia burden of disease: a systematic review of the cost-utility literature for hemophilia. J Manag Care Spec Pharm. 2018;24(7):632-42. Review.","journal-title":"J Manag Care Spec Pharm"},{"issue":"5","key":"key20220503090854_B17","doi-asserted-by":"crossref","first-page":"842","DOI":"10.7326\/0003-4819-89-5-842","article-title":"Clinical Investigators and the pharmaceutical industry","volume":"89","author":"Kunin","year":"1978","unstructured":"17. Kunin CM. Clinical Investigators and the pharmaceutical industry. Ann Intern Med. 1978;89(5 Pt 2 Suppl):842-5.","journal-title":"Ann Intern Med"},{"issue":"20","key":"key20220503090854_B18","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJM200005183422009","article-title":"Is academic medicine for sale?","volume":"342","author":"Angell","year":"2000","unstructured":"18. Angell M. Is academic medicine for sale? N Engl J Med. 2000;342(20):1516-8.","journal-title":"N Engl J Med"},{"issue":"1","key":"key20220503090854_B19","first-page":"38","article-title":"Avalia\u00e7\u00e3o do risco de vi\u00e9s de ensaios cl\u00ednicos randomizados pela ferramenta da colabora\u00e7\u00e3o Cochrane","volume":"18","author":"Carvalho","year":"2013","unstructured":"19. Carvalho AP, Silva V, Grande AJ. Avalia\u00e7\u00e3o do risco de vi\u00e9s de ensaios cl\u00ednicos randomizados pela ferramenta da colabora\u00e7\u00e3o Cochrane. Diagn Tratamento. 2013;18(1):38-44.","journal-title":"Diagn Tratamento"},{"key":"key20220503090854_B20","author":"Cochrane Training","year":"2021","unstructured":"20. Cochrane Training. Cochrane Handbook for Systematic Reviews of Interventions. London: Cochrane; 2021 [cited 2021 Mar 6]. Available from: https:\/\/training.cochrane.org\/handbook","journal-title":"Cochrane Handbook for Systematic Reviews of Interventions"},{"issue":"2","key":"key20220503090854_B21","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1046\/j.1537-2995.2002.00039.x","article-title":"Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B","volume":"42","author":"Ewenstein","year":"2002","unstructured":"21. Ewenstein BM, Joist JH, Shapiro AD, Hofstra TC, Leissinger CA, Seremetis SV, Broder M, Mueller-Velten G, Schwartz BA; Mononine Comparison Study Group. Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion. 2002;42(2):190-7.","journal-title":"Transfusion"},{"issue":"5","key":"key20220503090854_B22","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2516.2004.00932.x","article-title":"Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma\/albumin-free method: Pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A","volume":"10","author":"Tarantino","year":"2004","unstructured":"22. Tarantino MD, Collins PW, Hay CR, Shapiro AD, Gruppo RA, Berntorp E, Bray GL, Tonetta SA, Schroth PC, Retzios AD, Rogy SS, Sensel MG, Ewenstein BM; RAHF-PFM Clinical Study Group. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma\/albumin-free method: Pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia. 2004;10(5):428-37.","journal-title":"Haemophilia"},{"issue":"2","key":"key20220503090854_B23","first-page":"217","article-title":"Surgical evaluation of a recombinant factor VIII prepared using a plasma\/albumin-free method: efficacy and safety of advate in previously treated patients","volume":"100","author":"N\u00e9grier","year":"2008","unstructured":"23. N\u00e9grier C, Shapiro A, Berntorp E, Pabinger I, Tarantino M, Retzios A, et al. Surgical evaluation of a recombinant factor VIII prepared using a plasma\/albumin-free method: efficacy and safety of advate in previously treated patients. Thromb Haemost. 2008;100(2):217-23.","journal-title":"Thromb Haemost"},{"issue":"2","key":"key20220503090854_B24","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/blood-2006-04-017988","article-title":"A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study","volume":"109","author":"Astermark","year":"2007","unstructured":"24. Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, Waters J, Berntorp E; FENOC Study Group. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood. 2007;109(2):546-51.","journal-title":"Blood"},{"issue":"13","key":"key20220503090854_B25","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJM198109243051301","article-title":"The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with haemophilia A and antibodies to factor VIII: a double blind clinical trial","volume":"305","author":"Sjamsoedin","year":"1981","unstructured":"25. Sjamsoedin LJ, Heijnen L, Mauser-Bunschoten EP, van Geijlswijk JL, van Houwelingen H, van Asten P, et al. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with haemophilia A and antibodies to factor VIII: a double blind clinical trial. N Engl J Med. 1981;305(13):717-21.","journal-title":"N Engl J Med"},{"issue":"2","key":"key20220503090854_B26","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000118628","article-title":"Pharmacokinetics, efficacy and safety of IMMUNATE\u00ae Solvent\/Detergent (IMMUNATE\u00ae S\/D) in previously treated patients with severe hemophilia A: results of a prospective, multicenter, open-label phase III study","volume":"119","author":"Nemes","year":"2008","unstructured":"26. Nemes L, Lissitchkov T, Dobaczewski G, Klukowska A, Komrska V, Zimmermann R, et al. Pharmacokinetics, efficacy and safety of IMMUNATE\u00ae Solvent\/Detergent (IMMUNATE\u00ae S\/D) in previously treated patients with severe hemophilia A: results of a prospective, multicenter, open-label phase III study. Acta Haematol. 2008;119(2):89-97.","journal-title":"Acta Haematol"},{"issue":"6","key":"key20220503090854_B27","first-page":"912","article-title":"Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors","volume":"80","author":"Key","year":"1998","unstructured":"27. Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost. 1998;80(6):912-8.","journal-title":"Thromb Haemost"},{"issue":"4","key":"key20220503090854_B28","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1046\/j.1365-2516.1999.00319.x","article-title":"Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency","volume":"5","author":"Scharrer","year":"1999","unstructured":"28. Scharrer I. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency. Haemophilia. 1999;5(4):253-9.","journal-title":"Haemophilia"},{"issue":"5","key":"key20220503090854_B29","first-page":"773","article-title":"Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery","volume":"80","author":"Shapiro","year":"1998","unstructured":"29. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost. 1998;80(5):773-8.","journal-title":"Thromb Haemost"},{"issue":"4","key":"key20220503090854_B30","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1160\/TH05-07-0510","article-title":"Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial","volume":"95","author":"Kavakli","year":"2006","unstructured":"30. Kavakli K, Makris M, Zulfikar B, Erhardtsen E, Abrams ZS, Kenet G; NovoSeven trial (F7HAEM-1510) investigators. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. Thromb Haemost. 2006;95(4):600-5.","journal-title":"Thromb Haemost"},{"issue":"2","key":"key20220503090854_B31","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1365-2516.2007.01601.x","article-title":"Single 270 microg kg(-1) -dose rFVIIa vs. standard 90 microgkg(-1) -dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison","volume":"14","author":"Young","year":"2008","unstructured":"31. Young G, Shafer FE, Rojas P, Seremetis S. Single 270 microg kg(-1) -dose rFVIIa vs. standard 90 microgkg(-1) -dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia. 2008;14(2):287-94.","journal-title":"Haemophilia"},{"issue":"3","key":"key20220503090854_B32","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1590\/1983-80422015233082","article-title":"Eticidade do uso de placebo em pesquisa cl\u00ednica: proposta de algoritmos decis\u00f3rios","volume":"23","author":"Fregnani","year":"2015","unstructured":"32. Fregnani JH, Carvalho AL, Paranhos FR, Viana LS, Serrano SV, C\u00e1rcano F, et al. Eticidade do uso de placebo em pesquisa cl\u00ednica: proposta de algoritmos decis\u00f3rios. Rev Bio\u00e9t. 2015;23(3):456-67.","journal-title":"Rev Bio\u00e9t"},{"key":"key20220503090854_B33","first-page":"1","volume-title":"Epidemiologia Cl\u00ednica:elementos essenciais","author":"Fletcher","year":"2006","unstructured":"33. Fletcher RH, Fletcher SW. Epidemiologia Cl\u00ednica:elementos essenciais. 4a ed. Porto Alegre: Artmed; 2006. p. 1-18.","edition":"4a"},{"issue":"2","key":"key20220503090854_B34","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1590\/S0103-507X2009000200016","article-title":"How to assess intensive care randomized trials","volume":"21","author":"Buehler","year":"2009","unstructured":"34. Buehler AM, Cavalcanti AB, Suzumura EA, Carballo MT, Berwanger O. How to assess intensive care randomized trials. Rev Bras Ter Intensiva. 2009; 21(2):219-25.","journal-title":"Rev Bras Ter Intensiva"},{"issue":"10","key":"key20220503090854_B35","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2519\/jospt.2018.0705","article-title":"Blinding: linking evidence to practice","volume":"48","author":"Kamper","year":"2018","unstructured":"35. Kamper SJ. Blinding: linking evidence to practice. J Orthop Sports Phys Ther. 2018;48(10):825-6.","journal-title":"J Orthop Sports Phys Ther"},{"issue":"5","key":"key20220503090854_B36","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias: Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","unstructured":"36. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA.1995;273(5):408-12.","journal-title":"JAMA"},{"issue":"9","key":"key20220503090854_B37","doi-asserted-by":"crossref","first-page":"730","DOI":"10.2519\/jospt.2018.0704","article-title":"Randomization: linking evidence to practice","volume":"48","author":"Kamper","year":"2018","unstructured":"37. Kamper SJ. Randomization: linking evidence to practice. J Orthop Sports Phys Ther. 2018;48(9):730-1.","journal-title":"J Orthop Sports Phys Ther"},{"key":"key20220503090854_B38","doi-asserted-by":"crossref","DOI":"10.1186\/s12891-015-0825-6","article-title":"The effect of journal impact factor, reporting conflicts, and reporting funding sources, on standardized effect sizes in back pain trials: A systematic review and meta-regression","volume":"16","author":"Froud","year":"2015","unstructured":"38. Froud R, Bj\u00f8rkli T, Bright P, Rajendran D, Buchbinder R, Underwood M, et al. The effect of journal impact factor, reporting conflicts, and reporting funding sources, on standardized effect sizes in back pain trials: A systematic review and meta-regression. BMC Musculoskelet Disord. 2015;16:370. Review.","journal-title":"BMC Musculoskelet Disord"},{"issue":"5","key":"key20220503090854_B39","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/bcpt.12613","article-title":"The first decade with the swedish prescribed drug register - a systematic review of the output in the scientific literature","volume":"119","author":"Wallerstedt","year":"2016","unstructured":"39. Wallerstedt SM, Wettermark B, Hoffmann M. The first decade with the swedish prescribed drug register - a systematic review of the output in the scientific literature. Basic Clin Pharmacol Toxicol. 2016;119(5):464-9. Review.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"3","key":"key20220503090854_B40","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1590\/S0104-59702012000300008","article-title":"Conflitos de interesse na pesquisa, produ\u00e7\u00e3o e divulga\u00e7\u00e3o de medicamentos","volume":"19","author":"Palma","year":"2012","unstructured":"40. Palma A, Vila\u00e7a MM. Conflitos de interesse na pesquisa, produ\u00e7\u00e3o e divulga\u00e7\u00e3o de medicamentos. Hist Cienc Saude - Manguinhos. 2012;19(3):919-32.","journal-title":"Hist Cienc Saude - Manguinhos"},{"issue":"3","key":"key20220503090854_B41","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1590\/1983-80422014223033","article-title":"Conflito de interesses em ensaios cl\u00ednicos iniciais envolvendo pacientes com neoplasia de pulm\u00e3o","volume":"22","author":"Santos","year":"2014","unstructured":"41. Santos M, Silva DA, Paranhos FR. Conflito de interesses em ensaios cl\u00ednicos iniciais envolvendo pacientes com neoplasia de pulm\u00e3o. Rev Bio\u00e9t. 2014;22(3):500-8.","journal-title":"Rev Bio\u00e9t"},{"issue":"3","key":"key20220503090854_B42","doi-asserted-by":"crossref","first-page":"196","DOI":"10.5327\/Z2447-212320202000054","article-title":"Cardiovascular drug labeling: Do they have information on necessary precautions for older people?","volume":"14","author":"Marques","year":"2020","unstructured":"42. Marques LO, Vasconcelos RC, Baldoni AO, Pestana AC, Chequer FM. Cardiovascular drug labeling: Do they have information on necessary precautions for older people? Geriatr Gerontol Aging. 2020;14(3):196-202.","journal-title":"Geriatr Gerontol Aging"}],"container-title":["Einstein (S\u00e3o Paulo)"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T13:09:33Z","timestamp":1651583373000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.einstein.br\/article\/quality-of-clinical-studies-present-in-the-package-inserts-of-coagulation-factors-used-in-the-treatment-of-hemophilia\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":42,"alternative-id":["10.31744\/einstein_journal\/2022AO6859"],"URL":"https:\/\/doi.org\/10.31744\/einstein_journal\/2022ao6859","relation":{},"ISSN":["1679-4508","2317-6385"],"issn-type":[{"type":"print","value":"1679-4508"},{"type":"electronic","value":"2317-6385"}],"subject":[],"published":{"date-parts":[[2022]]},"article-number":"eAO6859"}}